BF Biosciences Limited reported a strong financial performance for the year ended 30 June 2026
Filed as: Financial Results for the Year Ended 2026-06-30
Summary
BF Biosciences Limited reported a strong financial performance for the year ended 30 June 2026, with revenue reaching Rs 9.46 billion and net profit increasing to Rs 632 million.
Read the original filingFigures in the filing
| Item | This period | Period before | Change |
|---|---|---|---|
| Revenue | PKR 9.46 billion | PKR 5.84 billion | +62.0% |
| Net Profit | PKR 632 million | PKR 447 million | +41.4% |
| Gross Profit | PKR 4.09 billion | PKR 2.29 billion | +78.7% |
| Earnings Per Share (EPS) | PKR 7.16 per share | PKR 5.52 per share | +29.7% |
| Cash and Cash Equivalents | PKR 249 million | PKR 322 million | -22.7% |
Amounts are in Pakistani rupees as stated in the filing (M = million, B = billion).
What the filing says
- Revenue increased significantly by 62.03% to Rs 9.46 billion compared to Rs 5.84 billion in the prior year.
- Net profit rose by 41.38% to Rs 632 million from Rs 447 million, indicating strong profitability.
- Gross profit improved to Rs 4.09 billion, reflecting a 78.68% increase from the previous year's Rs 2.29 billion.
BF Biosciences Limited (BFBIO) on Nafa
Last price Rs 135.48 · Pharmaceuticals · You can own BFBIO shares from your phone.
More BFBIO announcements
- NoticeTransmission of Quarterly Financial Statements for the Period Ended 30-09-2026
- NoticeCertified true copy of the resolutions passed in the Annual General Meeting of the Company
- NoticeAnnual Progress Report for the Year Ended June 30, 2026
- Financial resultBF Biosciences Limited reported a net profit of Rs 184.88 million for the first quarter ended 30 September 2026Filed as: Financial Results for the Quarter Ended 30-09-2026
- NoticeBoard Meeting
- NoticeTransmission of Annual Financial Statements for the Year Ended 30-06-2026
Source: BF Biosciences Limited's filing with the Pakistan Stock Exchange. The summary and figures on this page are extracted from the filing by software and can contain errors; the filing itself is the record. This page describes the filing. It is not investment advice and Nafa does not recommend any stock. Investing in securities involves risk, including possible loss of principal.